ARS Pharmaceuticals (NASDAQ: SPRY) has appointed Donn Casale as president, effective June 1, 2026, with Richard Lowenthal continuing to lead as CEO. Mr. Casale brings 25 years of biopharmaceutical commercial leadership...
SVB Securities launched coverage of ARS Pharmaceuticals (NASDAQ:SPRY) with an “outperform” rating and $14 price target. The stock closed at $7.12 on Dec. 12. ARS is developing neffy, an intranasal epinephrine product in...